RAPT Therapeutics stock (US74933X1090): Biotech innovator in immunology

RAPT Therapeutics focuses on oral small-molecule drugs that modulate immune cell trafficking to treat autoimmune disorders and cancers. The company recently reported progress in its pipeline, including updates on RPT193 and tivocemab, according to investors.rapt.com as of 05/12/2026. Shares traded at 58.02 USD on Nasdaq as of recent data from TradingKey.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

RAPT Therapeutics: core business model

RAPT Therapeutics operates in the biotechnology sector, specializing in oral small-molecule therapies that inhibit immune cell migration. Its proprietary platform targets chemokine receptors to address unmet needs in autoimmune diseases like atopic dermatitis and oncology indications. The approach aims to provide orally available alternatives to injectable biologics, potentially improving patient compliance. RAPT was founded in 2015 and went public on Nasdaq in 2019 under ticker RAPT.

The company's lead candidates include RPT193, a CCR4 antagonist in Phase 2 for atopic dermatitis, and tivocemab (RPT835), a CCR2 inhibitor. RAPT collaborates with partners like Takeda for certain programs, providing non-dilutive funding and validation. As a clinical-stage biotech, RAPT has no approved products yet, relying on cash reserves and milestones for operations.

Main revenue and product drivers for RAPT Therapeutics

Future revenue will stem from potential approvals and commercialization of pipeline assets. RPT193 targets T-cell migration in inflammatory skin diseases, with topline data expected from ongoing trials. Tivocemab addresses monocyte recruitment in solid tumors. Milestone payments from partnerships, such as the Takeda deal for CCR2 inhibitors, represent near-term cash inflows reported in SEC filings.

Preclinical programs expand the pipeline into additional autoimmune and oncology areas. RAPT's drug discovery leverages structure-based design for high selectivity. For US investors, RAPT's Nasdaq listing and focus on high-prevalence diseases like atopic dermatitis offer exposure to immunology innovation amid growing biologic markets.

Industry trends and competitive position

The immunology market is projected to exceed $100 billion by 2030, driven by rising autoimmune disease prevalence in the US. Competitors include biologics giants like AbbVie and emerging oral therapy players like Incyte. RAPT differentiates with its oral TRAFFIC platform, potentially capturing market share if clinical success is achieved.

Why RAPT Therapeutics matters for US investors

RAPT provides US investors access to next-generation oral immunotherapies via its Nasdaq listing. With strong US headquarters in South San Francisco and trials enrolling American patients, it aligns with domestic healthcare demands. The biotech's progress could benefit from IRA provisions supporting innovative drugs.

Conclusion

RAPT Therapeutics advances its oral immunology pipeline amid competitive biotech landscapes. Clinical milestones and partnerships position it for potential growth, though biotech risks remain. Investors track upcoming trial data for direction on this Nasdaq-listed name.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.